1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Cell & Gene Therapies

Cell And Gene Therapy Field Sees Opportunity Under Trump

 
• By Michael McCaughan

The cell and gene therapy field has reached an inflection point in the US as the second Trump Administration begins and advocates argue the sector could fit well with the “MAHA” agenda.

Cell and gene therapies are at a breakout point, said Alliance for Regenerative Medicine CEO Tim Hunt. (Shutterstock)
Key Takeaways
  • Cell and gene therapy advocates believe their products philosophically fit with the Make America Healthy Again initiative.
  • The Trump Administration also could bring many opportunities, such as a more favorable M&A climate, they argued.
  • ARCH Venture Partners Managing Director Keith Crandell said start-up companies much proactively educate Trump’s health team.

Cell and gene therapy advocates believe they can make the case that the products are a good fit with the incoming Trump Administration’s health care vision.

“I would argue there is a strong philosophical alignment with aspects of the ‘Make America Healthy Again’ posture,” Alliance for Regenerative Medicine CEO Tim Hunt declared during ARM’s 13 January...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Legislation

EU Council Could Adopt Pharma Reform Package Next Week, But Disputes Risk A Year’s Delay

 
• By Eliza Slawther

The Council of the EU wants to adopt its negotiating position on the reform of the general pharmaceutical legislation “sooner, rather than later,” but divergence between member states could push negotiations back another year, a European Commission policy officer said today.

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.